版本:
中国

BRIEF-Kite receives U.S. FDA priority review for Axicabtagene Ciloleucel

May 26 Kite Pharma Inc

* Kite receives U.S. Food and Drug Administration priority review for Axicabtagene Ciloleucel

* Kite Pharma Inc - Prescription Drug User Fee Act (PDUFA) set for November 29, 2017

* Kite Pharma Inc - Biologics License Application submission based on primary analysis of ZUMA-1 Phase 2 trial

* Kite Pharma Inc - ‍Expects to submit its Market Authorization Application (MAA) of Axicabtagene Ciloleucel with European Medicines Agency in Q3 of 2017​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐